Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Exelixis
Neonc Technologies, Inc.
Aulos Bioscience, Inc.
ImmunityBio, Inc.
Bristol-Myers Squibb
Mayo Clinic
University of Pittsburgh
7 Hills Pharma, LLC
Incyte Corporation
Toray Industries, Inc
Sarcoma Oncology Research Center, LLC
Eli Lilly and Company
Molecular Templates, Inc.
Tempest Therapeutics
Fate Therapeutics
Nektar Therapeutics
Nektar Therapeutics
Jules Bordet Institute
Incyte Corporation
Apollomics (Australia) Pty. Ltd.
Five Prime Therapeutics, Inc.
MultiVir, Inc.
Celldex Therapeutics
Western Regional Medical Center
Bristol-Myers Squibb